Active Recombinant Human TNFSF14 Protein (Arg64-Val240), C-His tagged, Animal-free, Carrier-free

• Cat.No.: TNFSF14-303H
• Product Overview: Recombinant Human TNFSF14 Protein (Arg64-Val240) with C-His tag was expressed in E. coli and Animal-free as well as Carrier-free.

Specification

• Description: LIGHT, also known as TNFSF14 is a member of the TNF superfamily that produced by multiple immune cells such as activated T cells and immature dendritic cells (DCs). LIGHT is a 29 kDa type II transmembrane protein, which serves as a ligand for both lymphotoxin β receptor (LTβR) and TNFSF signaling receptors (TNFRSF14/HVEM). Besides, LIGHT can amplify NF-kB signaling pathway in T cells when presenting anti-CD3 antibody treatment. Additionally, LIGHT can stimulate T cell proliferation and IFN-expression via interacting with TNFRS13 /HVEM.
• Source: E. coli
• Species: Human
• Tag: His
• Form: Lyophilized
• Bio-activity: Measure by its ability to induce cytotoxicity in HT-29 cells in the presence of IFN-gamma. The ED50 for this effect is < 10 ng/mL.
• Molecular Mass: The protein has a calculated MW of 20.30 kDa.
  The protein migrates as 17 kDa under reducing condition (SDS-PAGE analysis).
• Protein length: Arg64-Val240
• Endotoxin: < 0.1 EU/μg of the protein by the LAL method.
• Purity: >98% as determined by SDS-PAGE analysis.
• Storage: This product is stable after storage at:
  -20 centigrade for 12 months in lyophilized state from date of receipt.
  -20 or -80 centigrade for 2 weeks under sterile conditions after reconstitution.
  Avoid repeated freeze/thaw cycles.
• Storage Buffer: Lyophilized from a 0.2 μm filtered solution of PBS containing 0.1% sarkosyl, pH 8.0.
• Reconstitution: It is recommended to reconstitute the lyophilized protein in sterile H2O to a concentration not less than 200 μg/mL and incubate the stock solution for at least 20 min to ensure sufficient re-dissolved.
• Shipping: The product is shipped with polar packs. Upon receipt, store it immediately at -20 centigrade or lower for long term storage.

Gene Information

• Gene Name: TNFSF14 tumor necrosis factor (ligand) superfamily, member 14 [ Homo sapiens (human) ]
• Official Symbol: TNFSF14
• Synonyms: TNFSF14; tumor necrosis factor (ligand) superfamily, member 14; tumor necrosis factor ligand superfamily member 14; CD258; HVEM L; LIGHT; LTg; delta transmembrane LIGHT; herpesvirus entry mediator A; herpesvirus entry mediator ligand; herpesvirus entry mediator-ligand; herpes virus entry mediator ligand; ligand for herpesvirus entry mediator; tumor necrosis factor receptor-like 2; tumor necrosis factor superfamily member LIGHT; TR2; HVEML
• Gene ID: 8740
• mRNA Refseq: NM_003807
• Protein Refseq: NP_003798
• MIM: 604520
• UniProt ID: O43557

Reviews

07/28/2020

The extended longevity of results gave us the confidence to delve deeper into complex biological processes.

08/01/2018

It was reassuring to know that the product's effects persisted, allowing for thorough and comprehensive research.

06/19/2016

The ability to obtain enduring results positively influenced the depth of our investigations.

Q&As

What are the primary changes induced by TNFSF14 in the tumor microenvironment?

TNFSF14, when delivered to or expressed within tumors, causes significant changes primarily through vascular normalization and generation of tertiary lymphoid structures.

What challenges remain in utilizing TNFSF14 for cancer immunotherapy?

While investigators have used multiple vectors to deliver TNFSF14 to tumor tissues, there are still improvements needed, and components within the human tumor microenvironment may impede translational efforts.

What does TNFSF14 stand for?

TNFSF14 stands for Tumor Necrosis Factor Superfamily Member 14.

How can TNFSF14 synergize with other immunotherapy modalities?

TNFSF14's changes in the tumor microenvironment can synergize with methods inducing anti-tumor immune responses, such as checkpoint inhibitors and tumor vaccines, improving immunotherapeutic strategies against cancer.

In what context has TNFSF14 been utilized to combat cancer?

TNFSF14 has been used in multiple tumor models, where it can be combined with other immunotherapy modalities to clear established solid tumors and treat metastatic events.

How long has TNFSF14 been in pre-clinical development?

TNFSF14 has been in pre-clinical development for over a decade.

What is the primary promise of TNFSF14 in the field of cancer immunotherapy?

TNFSF14 shows promise in enhancing treatment approaches in cancer immunotherapy.